Glucagon Receptor
Abbreviation: GCGR
Definition
A receptor found mainly in the liver that carries out glucagon's effects: raising liver glucose output, burning fat and increasing energy use.
Glucagon Receptor
The glucagon receptor (GCGR) is a class B G-protein-coupled receptor (GPCR) and the main way glucagon acts on the body. It is most plentiful in the liver but is also found in the kidneys, heart, fat tissue, brain and gut. When glucagon binds, the receptor switches on adenylyl cyclase through the stimulatory G-protein (Gαs), raising cyclic AMP (cAMP) inside the cell. That triggers protein kinase A (PKA) signaling, which makes the liver break down stored glycogen and make new glucose, raising blood sugar during fasting. GCGR signaling also promotes fat burning in the liver, amino acid breakdown and urea production.
Beyond its classic job of raising blood sugar, the glucagon receptor has drawn interest for its effects on fat metabolism and energy use. Activating it in the liver increases fat burning (beta-oxidation) and reduces the making of new fat, so the liver holds less triglyceride. In animal studies, activating the glucagon receptor has raised whole-body energy use through heat-producing processes, possibly including brown fat activation and wasteful “futile” chemical cycles. These properties have made the glucagon receptor an attractive part of multi-agonist drug design for metabolic disease.
Clinical Relevance to Retatrutide
Retatrutide is a triple-agonist peptide that acts on the glucagon receptor alongside the GLP-1 and GIP receptors. Its GCGR activity sets it apart from dual GLP-1/GIP agonists such as tirzepatide and is thought to shape its metabolic profile in a unique way. Glucagon receptor activation in the liver should increase fat burning and reduce fat build-up, which may explain the large drops in fatty liver seen in clinical studies. GCGR’s boost to energy use may also help sustain weight loss by partly offsetting the metabolic slowdown that comes with eating less. Balancing glucagon’s tendency to raise blood sugar against the glucose-lowering effects of GLP-1 and GIP activity is central to retatrutide’s design, letting it deliver metabolic benefits without unacceptable rises in blood glucose.